Adicet Bio Inc (NAS:ACET)
$ 1.44 -0.03 (-2.04%) Market Cap: 118.32 Mil Enterprise Value: -18.00 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 54/100

Adicet Bio Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 05:00PM GMT
Release Date Price: $2.1 (-4.55%)
John Newman
Canaccord Genuity Group Inc. - Analyst

Everyone for joining us here at the 43rd Annual Canaccord Genuity Growth Conference in Boston. I'm John Newman, I'm one of the senior biotech analysts here at the firm. So we're very excited to have Adicet with us today.

And joining us today is the CEO, Chen Schor. Chen, welcome. So Chen, I wondered if you could start off maybe just by giving us a very brief background on Adicet for those that don't know the company well. You've got an off-the-shelf CAR T approach, different target than others. Wondering if you could describe a bit for us.

Chen Schor
Adicet Bio, Inc. - President & CEO

Sure, absolutely. But first of all, John, thank you for inviting us. Adicet was founded in 2015 looking to develop a cell therapy that can result in meaningful benefits to patients, both in hematologic tumors and in solid tumors. And we're focusing on a specific type of -- cell type called the gamma-delta 1 T-cells.

Perhaps it might be helpful to understand the gamma-delta 1 asset class versus, for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot